Product Code: PHA0460
The global macular degeneration and other retinal diseases market is estimated at $14.85bn in 2018 and is expected to grow at a CAGR of 6.7% during the forecast period.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 176-page report you will receive 110 charts - all unavailable elsewhere.
The 176-page report provides clear detailed insight into the macular degeneration (AMD) and other reginal diseases drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Global AMD and Other Retinal Diseases Market forecasts from 2019-2029
Revenue forecasts for Global AMD and Other Retinal Diseases Drugs Market by Disease Segment from 2019-2029:
- Wet AMD
- Dry AMD
- Diabetic Retinopathy
- Other Retinal Diseases
Revenue forecasts for Global AMD and Other Retinal Diseases Drugs Market by Product from 2019-2029:
Revenue forecasts for the Global AMD and Other Retinal Diseases Drugs Market by Region from 2019-2029:
- Rest of the World
Discussion and profiles of the below selected leading companies:
- Acucela, Inc.
- Allergan Plc
- Bayer AG
- F. Hoffman-La Roche, Ltd.
- GlaxoSmithKline Pharmaceuticals, Ltd.
- IVERIC bio, Inc.
- Novartis AG
- Pfizer, Inc.
- Regeneron Pharmaceuticals
- Valent Pharmaceuticals International, Plc
Analysis of the Drivers, Restraints, Opportunities and Threats of the global AMD and other retinal diseases market
- The report also includes a SWOT and STEP analysis of the global AMD and other retinal diseases market
- Discussion on the pipeline for Wet AMD. Dry AMD and Diabetic Retinopathy
Key questions answered by this report:
- How is the retinal diseases market evolving and what are the market prospects from 2018?
- What forces stimulate and restrain that market?
- What are the sales figures for retinal diseases?
- How will revenues of retinal diseases segments grow over the forecast period, 2019 to 2029?
- How will individual product sales develop to 2029?
- Which R&D pipeline products are likely to dominate the market in the next ten years, and what are their sales potentials?
- Which submarkets and national markets form the main drivers of the overall world market to 2029?
- How will social, technological, economic and political forces influence regional markets and world-level submarkets?
- How will market shares of top countries change by 2029 - with their revenues - and which regions will lead the market in 2029?
- Who are the leading companies and what are their prospects over the forecasted period?
Visiongain's study is intended for anyone requiring commercial analyses for the macular degeneration (AMD) and other reginal diseases drugs market. You find data, trends and predictions.
Buy our report today Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.
Visiongain is a trading partner with the US Federal Government.
Table of Contents
1. Report Overview
- 1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
- 1.2 Why You Should Read This Report
- 1.3 How This Report Delivers
- 1.4 Main Questions Answered by This Analysis
- 1.5 Who Is This Study For?
- 1.6 Methods of Research and Analysis
- 1.7 Frequently Asked Questions (FAQs)
- 1.8 Some Associated Reports
- 1.9 About Visiongain
2. World AMD and Other Disease Market, 2018
- 2.1 What are Retinal Diseases?
- 2.2 Types of Retinal Diseases
- 2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
- 2.4 Nearly 200 Million People with AMD?
- 2.5 Over 100 Million with DR
- 2.6 First RVO Estimates Suggest Patient Population of 16 Million
- 2.7 Market to Grow Rapidly by 2029
- 2.8 Eylea Became Leading Drug in the Market
- 2.9 Regeneron the Leading Presence in the Market
- 2.10 Which are the Most Significant Disease Areas for the Market?
3. Retinal Disease Market Subsectors, 2018
- 3.1 Wet AMD Still the Main Source of Revenue in the Market
- 3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
- 3.2.1 Revenue Forecasting for Wet AMD segment, 2019-2029
- 3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
- 3.3.1 Dry AMD Segment to Emerge in the Forecast Period
- 3.4 DR: Coming into Clinical Focus, with DME the Main Target
- 3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
- 3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
- 3.6 Projections of all Segments, 2019-2029
4. Approved Products in the AMD and Other Retinal Diseases Market, 2019-2029
- 4.1 Will the Current Products Dominate the Market through 2029?
- 4.2 Lucentis: Second Leading Drug in the Market
- 4.2.1 Positive Revenue Growth Shown in Past: 2014-2017
- 4.2.2 Shadow of Avastin Still Hangs Over Lucentis
- 4.2.3 Lucentis/Avastin Matters
- 4.2.4 Eylea: The Bigger Threat to Lucentis?
- 4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves into DME and Beyond
- 4.2.6 Improving Cost and Compliance for Lucentis
- 4.2.7 Lucentis Revenue Forecast 2019-2029
- 4.2.8 Will Loss of Physician Goodwill Harm Lucentis' Growth?
- 4.3 Eylea: Holds the Throne?
- 4.3.1 Increasing Revenue Growth in Past: Outside the US Sale Amplified
- 4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
- 4.3.3 First Wave of Eylea's Expansion Finally Beginning to Break?
- 4.3.4 Eylea into DME and Other New Indications
- 4.3.5 Eylea Revenue Forecast 2019-2029
- 4.3.6 How Far Can Eylea's Momentum Carry It?
- 4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
- 4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
- 4.4.2 Judicial Review Averted in the UK by Price Adjustment
- 4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
- 4.4.4 Roche and Novartis Challenge CATT's Headline Conclusions
- 4.4.5 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
- 4.4.6 Avastin Revenue Forecast, 2019-2029
- 4.4.7 Will Anything Dislodge Avastin from its Central Position?
- 4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
- 4.5.1 Visudyne Revenue Forecast, 2019-2029
- 4.6 Other Drugs for Macular Degeneration and Other Retinal Diseases
- 4.6.1 Other Drugs Revenue Forecast, 2019-2029
5. Pipeline for Wet AMD Segment
- 5.1 The Leading Pipeline Candidates
- 5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
- 5.2.1 Three Phase III Trials to Confirm Fovista's Outstanding Phase II Results
- 5.2.2 Ophthotech Goes Public to Fund Phase III Effort
- 5.2.3 Ophthotech Partners with Novartis for Fovista
- 5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
- 5.2.5 The Move towards Combination Therapies
- 5.3 Other Growth Factor Targets in the Pipeline
- 5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
- 5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
- 5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
- 5.4 APL-2: Evaluation for the treatment of patients with Geographic Atrophy (GA) related to AMD
- 5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
- 5.4.2 Binding Affinity Comparable to Eylea
- 5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
- 5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
- 5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
- 5.5.3 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
- 5.5.4 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
- 5.5.5 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
- 5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
- 5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
- 5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
- 5.7 Other Targets Under Investigation in wAMD Drug Development
- 5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
- 5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
- 5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
- 5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
- 5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
- 5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
- 5.7.7 Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
- 5.7.8 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
- 5.7.9 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
- 5.8 Regenerative Medicine Approaches
- 5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
- 5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
- 5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
6. Pipeline for Dry AMD Segment
- 6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
- 6.2 MC-1101 (MacuCLEAR): Leading the Pack?
- 6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
- 6.2.2 Novel Endpoints in Phase III Study
- 6.2.3 Can MacuCLEAR Make It?
- 6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase III
- 6.3.1 Study Result Declared in May 2016
- 6.3.2 Other Visual Cycle Modulators
- 6.4 High Hopes for Complement Inhibition in Dry AMD
- 6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
- 6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
- 6.5 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
- 6.5.1 Iluvien (Alimera Sciences): Study terminated
- 6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
- 6.6 Neuroprotection: One of Modern Medicine's Holy Grails
- 6.6.1 Tandospirone (Alcon): Not effective in GA
- 6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
- 6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
- 6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
- 6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
- 6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
- 6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
- 6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
- 6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
- 6.7.5 First iPSC Trial in Japan in Dry AMD Patients
- 6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
- 6.8 Other Treatments for Dry AMD
7. Pipeline for Diabetic Retinopathy Segment
- 7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
- 7.2 Lucentis: The Game Changer for DR?
- 7.3 New Anti-VEGF Additions
- 7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
- 7.4 Steroids in Development for DR
- 7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
- 7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
- 7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
- 7.4.4 Cortiject (Santen): Prodrug Candidate
- 7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
- 7.5 Other Products in Development for DR
- 7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
- 7.5.2 Vitreosolve (Innovations in Sight): Will a Phase III Trial Be Initiated?
- 7.5.3 TriLipix (Abbott): No New Development for Promising Drug
- 7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
8. Regional Market Breakdown, 2019-2029
- 8.1 Which Markets Hold the Most Revenue Growth Potential?
- 8.2 The US: Leading Market for Retinal Diseases
- 8.3 Japan: Strong Market Potential
- 8.4 EU5: Ageing Populations to Drive Market Growth
- 8.5 BRIC Nations: The Biggest Growth Driver for the Market
9. Leading Companies in Global AMD and Other Retinal Diseases Market, 2018
- 9.1 Novartis AG
- 9.1.1 Company Overview
- 9.1.2 Financials
- 9.1.3 Key News
- 9.2 F. Hoffmann-La Roche, Ltd.
- 9.2.1 Company Overview
- 9.2.2 Financials
- 9.2.3 Key News
- 9.3 Bayer AG
- 9.3.1 Company Overview
- 9.3.2 Financials
- 9.3.3 Key News
- 9.4 Regeneron Pharmaceuticals
- 9.4.1 Company Overview
- 9.4.2 Financials
- 9.4.3 Key News
- 9.5 Valent Pharmaceuticals International, Inc.
- 9.5.1 Company Overview
- 9.5.2 Financials
- 9.5.3 Key News
- 9.6 Pfizer Inc.
- 9.6.1 Company Overview
- 9.6.2 Financials
- 9.6.3 Key News
- 9.7 Acucela, Inc.
- 9.7.1 Company Overview
- 9.7.2 Key News
- 9.8 IVERIC bio, Inc.
- 9.8.1 Company Overview
- 9.8.2 Financials
- 9.8.3 Key News
- 9.9 GlaxoSmithKline Pharmaceuticals Ltd.
- 9.9.1 Company Overview
- 9.9.2 Financials
- 9.10 Allergan PLC
- 9.10.1 Company Overview
- 9.10.2 Financials
10. Qualitative Industry and Market Analysis
- 10.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
- 10.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
- 10.3 Opportunities: New Markets and R&D Synergies
- 10.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
- 10.5 Social: Low Diagnosis, Low Compliance
- 10.6 Technological: Innovation for the Eye
- 10.7 Economic: Off-Label Treatment and Reimbursement Issues
- 10.8 Political: The Demography and Diabetes Challenges
- 11.1 The Age of Lucentis: Nearing Its Conclusion?
- 11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
- 11.3 Indications Outside Wet AMD to Gain in Importance
- 11.4 Dry AMD Market Has Huge Potential
- 11.5 Fovista Most Prominent Among the Pipeline Candidates
- 11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain Report Evaluation Form